Melanoma Institute Australia shines at prestigious Cancer Research Awards
3 November 2018
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has won the top award for Outstanding Cancer Researcher of the Year. One of the world’s pre-eminent melanoma clinicians and researchers, Professor Long has changed the face of melanoma treatment around the world with her ground-breaking clinical trials tripling life expectancy for patients with advanced melanoma and curing a significant subset.
Fellow MIA Co-Medical Director, Professor Richard Scolyer, has been awarded The Professor Rob Sutherland AO Make a Difference Award, which is awarded in recognition of lasting impact and sustained progress to cancer care or research practice. Professor Scolyer is the world’s leading melanoma pathologist, each year receiving more than 2,000 cases for review and opinion from around the world. He recently co-edited the new WHO Classification of Skin Tumours, 4th Edition.
Also awarded were MIA’s Associate Professor Alex Menzies, who won the Outstanding Cancer Research Fellow Award with less than five years post-doctoral experience in research, and Associate Professor Anne Cust, who was awarded Outstanding Cancer Research Fellow with more than five years post-doctoral experience in research.
Associate Professor Menzies is a Medical Oncologist with research interest in clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Associate Professor Cust is an epidemiologist whose research focuses on melanoma epidemiology, prevention, early detection and survivorship and has a strong emphasis on translational outcomes.
Melanoma Institute Australia CEO Matthew Browne said it was a proud moment to see Melanoma Institute Australia’s research and clinical team centre stage at the prestigious awards night.
‘This is well deserved recognition for not only these award winners, but also the multi-disciplinary teams across MIA that work tirelessly to develop new treatments to save lives from melanoma,’ Mr Browne said.
‘My particular congratulations go to Professor Long for taking out the prestigious Outstanding Cancer Researcher of the Year Award. This is testament to her research and global thought leadership which has set the world on the path towards advanced melanoma becoming a chronic disease rather than a terminal one.
‘She was gracious in acknowledging the award was recognition of the whole team’s efforts at MIA, and particularly her long research partnership with Professor Richard Scolyer.
‘With the breakthroughs in melanoma treatment also set to revolutionise treatments for other cancers, Professor Long’s legacy will potentially impact millions across the globe.’
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.